Fermenta Biotech Q1FY27 Investor Presentation Released; Revenue ₹126.2 Crore
Fermenta Biotech's Q1FY27 revenue was ₹126.2 crore. Profit after tax declined 56% YoY to ₹9.5 crore. Human Nutrition revenue grew 24% QoQ. India's contribution to revenue rose to 47%. The company highlighted growth in APIs and Green Chemistry, while Animal Nutrition faced challenges. FSSAI approval for VITADEE Green® was received.
The announcement provides detailed financial results for the quarter and an investor presentation outlining the company's strategy and outlook. This information is material for investors to assess the company's performance and future prospects.
The company released its quarterly results and an investor presentation. While there are positive aspects like sequential growth in Human Nutrition and a stronger India market, the overall year-on-year financial performance shows a significant decline in revenue and profit, making the sentiment neutral.
Fermenta Biotech Limited has released its Investor Presentation for the first quarter of FY27, detailing its financial performance and strategic outlook.
The company reported consolidated revenue of ₹126.2 crore for Q1FY27, a decrease of 13% year-on-year but flat quarter-on-quarter. Excluding real estate, revenue stood at ₹124.3 crore, down 12% YoY and flat QoQ. EBITDA was ₹22.4 crore (down 39% YoY, down 11% QoQ), and Profit After Tax was ₹9.5 crore (down 56% YoY, down 49% QoQ). Diluted EPS was ₹3.34.
Key highlights include a sequential growth of 24% in Human Nutrition revenue to ₹76.5 crore, with segment volumes up 18% QoQ. India emerged as a stronger market, contributing 47% of consolidated revenue in April-June 2026, up from 35% a year prior. Growth was observed in 'Other APIs and Intermediates' (up 18% YoY) and 'Green Chemistry Solutions / Enzymes' (up 15% YoY). Animal nutrition, however, remained a soft spot with volumes down 52% QoQ and 20% YoY.
Post-quarter milestones include FSSAI approval for VITADEE Green® on July 6, 2026, and India's Great Mid-size Workplaces 2026 ranking. The YoY comparison is influenced by a strong Q1FY26 base that included non-recurring insurance income and real estate value unlocking.
The presentation also outlines Fermenta's strategic focus on innovation chemistry, expanding its portfolio in areas like plant-based Vitamin D3 (VITADEE Green®) and Calcifediol, and strengthening its global leadership in Vitamin D3. The company emphasizes its integrated manufacturing capabilities, customer-centric approach, and commitment to sustainability through green chemistry.
What to do with a filing like this
Fermenta Biotech Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fermenta Biotech Limited. Read the original for the full detail.